Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWP42003 in Ulcerative Colitis
NCT01562314Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- May 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing GWP42003 with Placebo (2 arms). Primary endpoint: Percentage of Participants Achieving Remission (Mayo Score <= 2) at 10 weeks. Started May 2012; status: completed.
02
Drugs
cannabidiol
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01562314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562314.